International Conference on Innovations for the Elimination and Control of Visceral Leishmaniasis (IEC-VL)

JH-Institute of Molecular Medicine, Jamia Hamdard, New Delhi-67

Nov 28-30, 2018

Detailed Program

Venue: Holiday Inn, Aerocity, New Delhi

Conference Programme

DAY 1: 28th November, 2018

08:15 – 09:00

Registration

Inaugration

09:00 - 09:05

Quran Recitation

09:05 - 09:10

Introduction and Bouquet presentation

Prof. Farhan J. Ahmad,
Dean, SIST, Jamia Hamdard, New Delhi

09:10 - 09:25

Welcome address by Chairman Organizing Committee

Prof. N. K. Ganguly,
Former Director Genral of Indian Council of Medical Research, New Delhi

09:40 – 09:50

Address by the Vice Chancellor, Host Institute

Prof. Seyed E. Hasnain,
Vice Chancellor, Jamia Hamdard, New Delhi

09:50 – 09:55

Vote of Thanks

Dr. A. Selvapandiyan,
JH-Institute of Molecular Medicine, Jamia Hamdard, New Delhi

09:55 - 09:56

National Anthem

 

Keynote Address

10:00 - 10:30

Chair

Prof. Seyed E. Hasnain,
Vice Chancellor, Jamia Hamdard, New Delhi

Address By

Prof. Shyam Sundar,
Banaras Hindu University, Varanasi, India
Title: Developing tools for the management of Kala-azar in its hinterland

 

10:30 - 11:00

High-Tea

A. VL and PKDL: Current status from control to elimination

11:00 - 12:20
Current Status

Chairs

Simon Croft
London School of Hygiene and Tropical Medicine, London, UK
 
Shyam Sundar,
Banaras Hindu University, Varanasi, UP, India

Suman Rijal,
DNDi (India), New Delhi, India

Title: Elimination of kala-azar in the Indian subcontinent: Lessons from elimination of other neglected diseases

Rajib Chowdhury / Md. Sohel Shomik,
National Institute of Preventive and Social Medicine, Bangladesh

Title: A path achieved towards kala-azar near-elimination in Bangladesh

Pradeep Das,
The Rajendra Memorial Research Institute of Medical Sciences, Patna, India

Title: Overview of VL in India, Past and Present

E. E. Zijlstra,
Rotterdam Centre for Tropical Medicine, Rotterdam, Netherlands

Title: PKDL a threat in kala- azar elimination strategy in Indian Subcontinent

12:20 - 13:00

Lunch

B. Impacts of Basic Science and Research - Genomics / Immunology / Epimodelling VL and PKDL: Current status from control to elimination

13:00 - 14:20
Genomics & Basic Sciences

Chairs

Hira Nakhasi,
Food and Drug Administration, Silver Spring, MD, USA
 
Mitali Chatterjee,
Institute of PG Medical Education & Research, Kolkata, India

Chittar Mal Gupta,
CDRI, Lucknow, India

Title: Myosin and profilin as possible drug targets in Leishmania

Jean C. Dujardin,
Institute Tropical Medicine, Antwerp, Belgium

Title: Novel methods to sequence parasite genome directly in clinical samples

Greg Matlashewski,
McGill Univ, Montreal, QC, Canada

Title: Development of CRISPR-Cas Genome Editing in Leishmania

Dan Zilberstein,
Technion, Israel Institute of Technology, Israel

Title: Arginine sensing in Leishmania is essential for intracellular development

 

14:20 - 15:40
Immunology

Chairs

Anuradha Dube,
CDRI, Lucknow, UP, India
 
Shaden Kamhawi,
The National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA

Abhay Satoskar,
Ohio State University, Ohio, USA

Title: The critical role of inflammatory monocytes in disease outcome of visceral leishmaniasis

Christian Engwerda,
University of Queensland, Lucia, Australia

Title: Host-directed immune therapy to help eliminate and control VL

Mitali Chatterjee,
Institute of PG Medical Education & Research, Kolkata, India

Title: Macrophage reprogramming and antigen presentation in PKDL

Roberto Badaro,
Federal University of Bahia, Brazil

Title: Immunotherapy co-adjuvant treatment for refractory Leishmaniasis

 

15:40 - 16:40
Epidemiology

Chairs

Nupur Roy,
National Vector Borne Disease Control Program, New Delhi, India
 
Jorge Alvar,
DNDi, Geneva, Switzerland

Graham Medley,
London School of Hygiene and Tropical Medicine, London, UK

Title: The pattern of diagnosed cases in time and space during elimination and post-elimination of VL in India

Om Prakash Singh,
Banaras Hindu University, Varanasi, UP, India

Title: Determinants of disease progression and role of asymptomatic Leishmania donovani infection in transmission

Nadira Karunaweera,
Colombo University, Sri Lanka

Title: Leishmania donovani variant that causes cutaneous leishmaniasis in Sri Lanka

16:40 - 17:20

Poster Session I and Tea

17:20 - 18:20
Tranmission

Chairs

Pradeep Das,
The Rajendra Memorial Research Institute of Medical Sciences, Patna, India
 
Mary Cameron,
London School of Hygiene and Tropical Medicine, London, UK

Shaden Kamhawi,
The National Institute of Allergy and Infectious Diseases, NIH, Rockville, USA

Title: Significance of Vector Challenge in Relation to Visceral Leishmaniasis Control: Deciphering Sand Fly-Transmitted Infections

Jorge Alvar,
DNDi, Geneva, Switzerland

Title: The role of PKDL patients in the VL transmission in Bangladesh

R. K. Dasgupta,
Ex. Joint Director, NVBDCP, New Delhi, India

Title: When to stop Indoor Residual Spray for Kala- azar elimination

 

18:20 - 19:20
PANEL I

PANEL DISCUSSION I:
Models for partnerships, programs and integration to combat VL

Chairs

N. K. Ganguly,
Former DG, Indian Council of Medical Research, New Delhi, India
 
A. P. Dash,
Vice Chancellor, Central University of Tamilnadu, Neelakudi, Thiruvarur - 610 005, Tamil Nadu

Members

1. P.K. Sen, National Vector Borne Disease Control Program, New Delhi, India
2. Neeraj Jain, PATH, New Delhi, India
3. Sanjay Sarin, FIND, New Delhi, India
4. Liz Clyman, BM Gates Foundation (India), New Delhi, India
5. Rashmi Shukla, NPO-NTD, WHO Country Office for India, New Delhi
6. Stefanie Meredith, KalaCORE/Mott MacDonald

20:00 - 21:00

Evening Reception: DINNER

DAY 2: 29th November, 2018

08:30 - 09:50
Drugs

Chairs

Syamal Roy,
National Institute of Pharmaceutical Education & Research, Kolkata, India
 
Dan Zilberstein,
Technion, Israel Institute of Technology, Israel

Neena Goel,
Central Drug Research Institute, Lucknow, India

Title: Drug discovery to combat VL in India

Fabiana Alves,
DNDi, Geneva, Switzerland

Title: Current and future perspectives for the development of innovative treatments for leishmaniasis

Syamal Roy,
National Institute of Pharmaceutical Education & Research, Kolkata, India

Title: Therapeutic role of cholesterol and cholesterol mimetics in experimental visceral leishmaniasis

Thomas Dorlo,
DNDi, Geneva, Switzerland

Title: PK/PD as a tool for the development and optimization of new therapies for VL

 

09:50 - 10:10

TEA

10:10 - 11:10
Diagnostic

Chairs

Suman Rijal,
DNDi, New Delhi
 
Greg Matlashewski,
McGill Univ, Montreal, QC, Canada

Poonam Salotra / Ruchi Singh
National Institute of Pathology (ICMR), New Delhi

Title: Post kala azar dermal leishmaniasis: Challenges in diagnosis and treatment

Sakib Burza,
Médecins Sans Frontières, New Delhi, India

Title: Diagnosis and management of VL-HIV coinfection within the elimination framework

Isra Cruz,
FIND, Geneva, Switzerland

Title: Unmet diagnostic needs in leishmaniasis

 

18:20 - 19:20
PANEL II

PANEL DISCUSSION II:
Innovations in communications and advocacy needed to sustain the elimination of VL

Chair

P. K. Sen,
NVB National Vector Borne Disease Control Program, New Delhi, India
 
N. K. Ganguly,
Former DG, Indian Council of Medical Research, New Delhi, India

Members

1. Amresh Kumar, PATH, New Delhi, India
2. M.P. Sharma, Additional Director cum SPO, Bihar
3. Mary Cameroon, LSHTM, London, UK
4. Mr. Amandeep Singh, Global Health Strategies, New Delhi, India
5. Pradeep Das, The Rajendra Memorial Research Institute of Medical Sciences, Patna, India
6. Jorge Alvar, DNDi, Geneva, Switzerland

12:00 – 12:40

LUNCH

 

12:40 - 14:20
Vaccines

Chair

Steve Reed,
The Infectious Disease Research Institute, Seattle, USA
 
Abhay Satoskar,
Ohio State University, Ohio, USA

Hira Nakhasi,
Food and Drug Administration, Silver Spring, MD, USA

Title: Second generation Leishmanization with a live attenuated markerless Leishmania vaccine candidate

Paul Kaye,
University of York, UK

Title: Strategies for vaccine development 2018-2023

Javier Moreno,
Institute of Health Carlos III (ISCIII), Spain

Title: Assessment of immunity against leishmaniasis

Steve Reed,
The Infectious Disease Research Institute, Seattle, WA, USA

Title: Clinical Development of Vaccines for Cutaneous and Visceral Leishmaniasis

Sanjay Singh,
Gennova Biopharmaceuticals, Pune, India

Title: Production process of Leishmania live attenuated vaccine

 

14:20 - 16:00
Data & Health Systems

Chair

Sakib Burza,
Médecins Sans Frontières, New Delhi, India
 
Amresh Kumar,
PATH, New Delhi, India

Dinesh Mondal,
International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh

Title: Operation research to support the control program in Bangladesh

Kingsuk Misra,
KalaCore, Kolkata, India

Title: Accelerated elimination through data driven decision making in active case detection

Mary Cameron,
London School of Hygiene and Tropical Medicine, London, UK

Title: SPEAK India consortium: working towards sustained elimination of visceral leishmaniasis (VL) in the Indian subcontinent

Philippe Guerin,
Infectious Disease Data Observatory, University of Oxford, UK

Title: Collaborating to optimize the efficacy of VL therapies: a VL global data platform

Jose Postigo,
World Health Organization, Geneva, Switzerland

Title: The role of WHO in the visceral leishmaniasis control and elimination programs in East Africa and South-East Asia

 

16:00 – 16:40

POSTER SESSION II & TEA

 

14:40 - 18:00
PANEL I

PANEL DISCUSSION III:
Key outcomes, position paper on research needs and opportunities to sustain VL elimination

Chairs

Piero Olliaro,
Centre for Tropical Diseases and Global Health
Nuffield Deaprtment of Medicine
University of Oxford, UK
 
N. K. Ganguly,
Former DG of ICMR, New Delhi, India
 
Simon Croft,
London School of Hygiene and Tropical Medicine, London, UK

Members

1. R. K. Das Gupta, Ex. Joint Director, National Vector Borne Disease Control Program, New Delhi, India
2. Hira Nahasi, FDA, Silver Spring, MD, USA
3. Sakib Burza, Médecins Sans Frontières, New Delhi, India
4. Saurabh Jain, WHO HQ, Geneva, Switzerland
5. Suman Rijal, DNDi, New Delhi, India
6. William Starbuck, Bill & Melinda Gates Foundation (India), New Delhi, India

DAY 3: 30th November, 2018

08:30 - 10:30

ORAL PRESENTATION FROM SELECTED INVESTIGATORS: Concurrent Sessions in 2 halls

HALL A
Concurrent Session 1A

Chairs

Piero Olliaro,
Centre for Tropical Diseases and Global Health
Nuffield Deaprtment of Medicine
University of Oxford, UK
 
N. K. Ganguly,
Former DG of ICMR, New Delhi, India
 
Simon Croft,
London School of Hygiene and Tropical Medicine, London, UK

 

Vimal Kumar Varun, DSIR, Ministry of Science & Technology, New Delhi, India
Farhat Afrin, Taibah University, Madina, Kingdom of Saudi Arabia
Title: Nanoliposomal artemisin: Hope towards elimination of visceral leishmaniasis
Md. Solomon M. Abay, Addis Ababa University, Addis Ababa, Ethiopia
----------------------------------
ORALS from Abstract:
1. Ritika Sengupta, IPGMER, Kolkata, India
Title: Loss of melanocytes and immune dysregulation in Indian Post Kala-azar Dermal Leishmaniasis
----------------------------------
2. Puja Tiwary, BHU, Varanasi, India
Title: Development of Phlebotomus argentipes colony for its application in Xenodiagnostic studies
----------------------------------
3. Samiran Saha, Visva Bharati, Shantiniketan, India
Title: Therapeutic and immune modulatory potential of new combination treatment by Tinospora cordifolia extracts and Amphotericin B against experimental visceral leishmaniasis.
---------------------------------
4. Smriti Tandon, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
Title: Modulation of amino acylation and editing mechanism of Leishmania leucyl tRNA synthetase by its connective polypeptide 1 (CP1) domain
---------------------------------
5. Kalpana , Department of Zoology, Panjab University, Chandigarh, India
Title: Antileishmanial studies of Salidroside against the SSG-sensitive and resistant strains of Leishmania donovani
----------------------------------

 

HALL B
Concurrent Session 1B

Chairs

Nadira Karunaweera,
Colombo University, Sri Lanka
Neena Goel,
CDRI, Lucknow, UP, India

 

Krishna Pandey, RMRI, Patna, India
Shailja Singh, Jawaharlal Nehru University, New Delhi, India
Anuradha Dube, CDRI, Lucknow, India
 
ORALS from Abstracts:
1. Kavita, JH-Institute of Molecular Medicine, Jamia Hamdard, New Delhi India
Title: Genetic discriminations to diagnose co-occurring Leptomonas with Leishmania in clinical samples
----------------------------------------
2. Preeti Yadav, Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India
Title: Palmitoyl acyltransferases of L. donovani : A novel druggable target for therapeutic interventions
----------------------------------------
3. Pavneet Kaur, CDRI, Lucknow, UP, India
Title: Identification of MAPK1 regulated proteins of Leishmania donovani by comparative proteome analysis
--------------------------------------
4. Kumar Avishek, National Institute of Pathology (ICMR), New Delhi, India Title: Genetically modified live attenuated Leishmania parasites as vaccine candidate against visceral leishmaniasis
-------------------------------------
5. M. A. Domagalska, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
Title: Direct sequencing of Leishmania genome in clinical samples: The next generation method for parasite tracking
---------------------------------------

 

10:30 - 11:10

POSTER SESSION III & TEA

 

11:10 - 12:10

ORAL PRESENTATION FROM SELECTED INVESTIGATORS: Concurrent Sessions in 2 halls. Continues…

HALL A
Concurrent Session 2A

Chairs

Javier Moreno,
Institute of Health Carlos III (ISCIII), Spain

 
Farhat Afrin,
Taibah University, Madina, Kingdom of Saudi Arabia

 

1. Angamuthu Selvapandiyan, JH-Institute of Molecular Medicine, Jamia Hamdard, New Delhi India
Title: Study and deletion of amastigote specific genes in Leishmania donovani for the development of live attenuated vaccine candidates
----------------------------------
2. Lloyd Chapman, London School of Hygiene and Tropical Medicine, London UK
Title: Quantifying the role of PKDL in the transmission of visceral leishmaniasis
----------------------------------
3. Sophie Owen, Liverpool School of Tropical Medicine, Liverpool, UK
---------------------------------

 

HALL B
Concurrent Session 2B

Chairs

Greg Matlashewski,
McGill University, Montreal, Canada
 
Hira Nakhasi,
USFDA, Silver Spring, MD USA

 

Krishna Pandey, RMRI, Patna, India
Shailja Singh, Jawaharlal Nehru University, New Delhi, India
Anuradha Dube, CDRI, Lucknow, India
 
ORALS from Abstracts:
1. Swati Saha, University of Delhi South Campus, New Delhi
Title: HAT2-dependent H4K10 acetylation modulates transcriptional activation in cell cycle stage –dependent manner
----------------------------------------
2. Niti Puri, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
Title: Heterogeneity in Mast Cell responses and their effects during infection by different Leishmania species may lead to immunity or evasion
----------------------------------------
3. Surendra Uranw, B. P. Koirala Institute of Health Sciences, Dharan, Nepal
Title: Changing epidemiological pattern of visceral leishmaniasis in Nepal: A case study
---------------------------------------

 

12:20 – 13:00

POSTER SESSION IV & TEA

 

13:00 – 13:40

LUNCH

 

13:40 – 14:30

PANEL DISCUSSION IV: Career and how to involve new investigators

Panel IV

Chairs

Madubala Rentala,
School of Life Sciences, Jawaharlal Nehru University, New Delhi, India

 
Greg Matlashewski,
McGill University, Montreal, QC, Canada

 

1. Sukhbir Kaur, Panjab University, Chandigarh, India
2. Gautam Saha, AHERF, Apollo Hospital, New Delhi, India
3. Charu Gupta, JHIMM, Jamia Hamdard, New Delhi, India
4. Dinesh Mondal, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh
5. Nadira Karunaweera, Colombo University, Sri Lanka
6. Syamal Roy, National Institute of Pharmaceutical Education & Research, Kolkata, India

 

12:30 – 15:00
Concluding Session

Chair

Suman Rijal,
DNDi, New Delhi

 

Simon Croft, London School of Hygiene and Tropical Medicine, London, UK
Title: Curtain-down remark to IEC-VL conference

 

15:00 – 15:20

TEA & DEPART

Sponsors and Partners